WO2011009039A3 - Produit pharmaceutique pour administration par voie orale comprenant mgbg et procédés de traitement de maladie - Google Patents
Produit pharmaceutique pour administration par voie orale comprenant mgbg et procédés de traitement de maladie Download PDFInfo
- Publication number
- WO2011009039A3 WO2011009039A3 PCT/US2010/042253 US2010042253W WO2011009039A3 WO 2011009039 A3 WO2011009039 A3 WO 2011009039A3 US 2010042253 W US2010042253 W US 2010042253W WO 2011009039 A3 WO2011009039 A3 WO 2011009039A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mgbg
- pharmaceutical
- methods
- oral delivery
- treating disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
Abstract
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES10800602T ES2715173T3 (es) | 2009-07-16 | 2010-07-16 | Producto farmacéutico para administración oral que comprende MGBG y métodos de tratamiento de enfermedades |
BR112012000862A BR112012000862A8 (pt) | 2009-07-16 | 2010-07-16 | composição farmacêutica oral, composição farmacêutica oral de baixa dose para administração crônica, método de tratamento ou retardo do inicio ou desenvolvimento de uma condição, método de tratamento da dor em um indivíduo que necessita deste medicamento, método de tratamento de uma condição em um indivíduo que necessita deste medicamento |
CA2768018A CA2768018C (fr) | 2009-07-16 | 2010-07-16 | Produit pharmaceutique pour administration par voie orale comprenant mgbg et procedes de traitement de maladie |
EP10800602.4A EP2453886B1 (fr) | 2009-07-16 | 2010-07-16 | Produit pharmaceutique pour administration par voie orale comprenant mgbg et procédés de traitement de maladie |
EP18210165.9A EP3473247A1 (fr) | 2009-07-16 | 2010-07-16 | Composition pour administration par voie orale comprenant la mgbg pour utilisation dans le traitement de la sclérose en plaque |
DK10800602.4T DK2453886T3 (en) | 2009-07-16 | 2010-07-16 | ORGANIC ADMINISTRATION COMPREHENSIVE MGBG AND DISEASE METHODS |
AU2010273277A AU2010273277B2 (en) | 2009-07-16 | 2010-07-16 | Pharmaceutical for oral delivery comprising MGBG and methods of treating disease |
NZ597488A NZ597488A (en) | 2009-07-16 | 2010-07-16 | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease |
CN201080041853.XA CN102686222B (zh) | 2009-07-16 | 2010-07-16 | 包含mgbg的口服递送药物以及治疗疾病的方法 |
JP2012520810A JP6112449B2 (ja) | 2009-07-16 | 2010-07-16 | Mgbgを含む経口送達用の医薬品および疾患を処置する方法 |
HK13103363.8A HK1176548A1 (en) | 2009-07-16 | 2013-03-18 | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease mgbg |
AU2016266049A AU2016266049B2 (en) | 2009-07-16 | 2016-12-01 | Pharmaceutical for oral delivery comprising MGBG and methods of treating disease |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22606009P | 2009-07-16 | 2009-07-16 | |
US61/226,060 | 2009-07-16 | ||
US29009509P | 2009-12-24 | 2009-12-24 | |
US61/290,095 | 2009-12-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011009039A2 WO2011009039A2 (fr) | 2011-01-20 |
WO2011009039A3 true WO2011009039A3 (fr) | 2011-06-16 |
Family
ID=43450234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/042253 WO2011009039A2 (fr) | 2009-07-16 | 2010-07-16 | Produit pharmaceutique pour administration par voie orale comprenant mgbg et procédés de traitement de maladie |
Country Status (12)
Country | Link |
---|---|
US (4) | US8258186B2 (fr) |
EP (2) | EP2453886B1 (fr) |
JP (4) | JP6112449B2 (fr) |
CN (2) | CN102686222B (fr) |
AU (2) | AU2010273277B2 (fr) |
BR (1) | BR112012000862A8 (fr) |
CA (1) | CA2768018C (fr) |
DK (1) | DK2453886T3 (fr) |
ES (1) | ES2715173T3 (fr) |
HK (1) | HK1176548A1 (fr) |
NZ (3) | NZ715686A (fr) |
WO (1) | WO2011009039A2 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3228310B1 (fr) | 2007-03-09 | 2021-05-05 | Pathologica LLC | Methylglyoxal bis(guanyl-hydrazone) pour la regulation de l'osteopontine chez un sujet |
ES2715173T3 (es) | 2009-07-16 | 2019-06-03 | Pathologica Llc | Producto farmacéutico para administración oral que comprende MGBG y métodos de tratamiento de enfermedades |
US9675566B2 (en) | 2009-07-16 | 2017-06-13 | Pathologica Llc | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing |
EP2665471B1 (fr) | 2011-01-19 | 2017-12-27 | Pathologica, LLC. | Formes posologiques pharmaceutiques orales à libération contrôlée comprenant de la mgbg |
WO2013083813A2 (fr) * | 2011-12-07 | 2013-06-13 | Universität Zürich | Modulateurs de la spermine/spermidine n'-acétyltransférase (ssat) et protéines associées à la ssat pour une utilisation dans la prévention ou le traitement de la polyarthrite rhumatoïde |
WO2014062552A1 (fr) * | 2012-10-15 | 2014-04-24 | Nestec Sa | Méthodes pour entretenir la santé oculaire et atténuer des maladies ophtalmiques chez les animaux |
EP2943189B1 (fr) * | 2013-01-08 | 2021-03-10 | Pathologica LLC | Mitoguazone pour le traitement de la sclérose en plaques progressive |
CA3015849A1 (fr) | 2016-03-25 | 2017-09-28 | Mark R. Burns | Polyamides biodisponibles |
WO2018027149A1 (fr) * | 2016-08-04 | 2018-02-08 | University Of Miami | Procédés de traitement du syndrome d'alport |
JP6840386B2 (ja) * | 2017-04-26 | 2021-03-10 | 学校法人 関西大学 | 細胞足場材料製造用組成物ならびに細胞足場材料およびその製造方法 |
EP4221698A1 (fr) | 2020-09-30 | 2023-08-09 | Aminex Therapeutics, Inc. | Combinaison de substances médicamenteuses à base d'inhibiteur de transport de polyamine et de dfmo |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5614557A (en) * | 1977-07-11 | 1997-03-25 | Marion Merrell Et Compagnie C/O Merrell Pharmaceuticals Inc. | Method of controlling tumor growth rate |
US20050159493A1 (en) * | 1997-10-27 | 2005-07-21 | Mcgrath Michael S. | Methods for modulating macrophage proliferation using polyamine analogs |
US20070078187A1 (en) * | 2005-09-23 | 2007-04-05 | Pathologica, Llc. | Methods for treating viral infections using polyamine analogs |
US20080262092A1 (en) * | 2007-03-09 | 2008-10-23 | Pathologica Llc. | Regulation of osteopontin |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4201788A (en) * | 1976-10-20 | 1980-05-06 | University Patents, Inc. | Process for alleviating proliferative skin diseases |
US5580715A (en) | 1994-08-05 | 1996-12-03 | The Regents Of The University Of California | Diagnosis of cancer having clonal macrophage involvement |
US5639600A (en) | 1994-08-05 | 1997-06-17 | The Regents Of The University Of California | Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement |
US5698563A (en) | 1995-01-13 | 1997-12-16 | Alteon Inc. | Bis- hydrazones! |
DE69733207T2 (de) | 1996-09-13 | 2006-02-02 | University of Florida Research Foundation, Inc., Gainesville | Verfahren zur hemmung von elf5a-biosynthese |
AR009380A1 (es) | 1996-10-21 | 2000-04-12 | Sumitomo Chemical Co | Proceso de preparacion de un derivado de piridazin-3-ona, util como herbicida, acido carboxilico de utilizacion en el mismo, sal de este ultimo y proceso para preparar dicho acido carboxilico |
US6083496A (en) | 1996-10-22 | 2000-07-04 | Universite Laval | Polyamine transport inhibitors |
US6172261B1 (en) | 1997-07-15 | 2001-01-09 | Oridigm Corporation | Polyamine analogues as therapeutic and diagnostic agents |
US5889061A (en) | 1997-10-15 | 1999-03-30 | Wisconsin Alumni Research Foundation | Conformationally restricted polyamines |
US8198334B2 (en) | 1997-10-27 | 2012-06-12 | Pathologica Llc | Methods for modulating macrophage proliferation in ocular disease using polyamine analogs |
US6169115B1 (en) * | 1998-05-22 | 2001-01-02 | Rima Kaddurah-Daouk | Use of aminoguanidine analogs for the treatment of diseases of the nervous system |
MXPA01011000A (es) | 1999-04-30 | 2003-06-30 | Slil Biomedical Corp | Analogos de poliaminas conformacionalmente restringidos como terapias para enfermedades. |
US6544541B1 (en) | 1999-06-02 | 2003-04-08 | Cardiovascular Solutions, Inc. | Devices and compounds for treating arterial restenosis |
JP2004513136A (ja) | 2000-11-08 | 2004-04-30 | スリル バイオメディカル コーポレーション | 抗癌剤として有用な新規ポリアミンアナログ−アミノ酸結合体 |
US7754765B2 (en) | 2000-12-01 | 2010-07-13 | Radical Vision Therapeutics Inc | Copper chelators for treating ocular inflammation |
US6963010B2 (en) | 2001-01-08 | 2005-11-08 | Mediquest Therapeutics, Inc. | Hydrophobic polyamine analogs and methods for their use |
US7045550B2 (en) | 2001-08-07 | 2006-05-16 | Wisconsin Alumni Research Foundation | Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy |
US6924095B2 (en) | 2001-08-15 | 2005-08-02 | The Regents Of The University Of California | Retrovirus isolated from mantle histiocytes in mantle cell lymphoma |
US7030126B2 (en) | 2001-11-16 | 2006-04-18 | Als Therapy Development Foundation, Inc. | Use of polyamine analogs for amyotrophic lateral sclerosis |
US7622117B2 (en) | 2002-04-17 | 2009-11-24 | Dynamis Therapeutics, Inc. | 3-deoxyglucosone and skin |
WO2004069174A2 (fr) | 2003-01-31 | 2004-08-19 | Slil Biomedical Corporation | Suivi et de traitement de la sclerose laterale amyotrophique |
US20050025825A1 (en) | 2003-07-31 | 2005-02-03 | Xanodyne Pharmacal, Inc. | Tranexamic acid formulations with reduced adverse effects |
WO2005041988A1 (fr) | 2003-10-22 | 2005-05-12 | University Of Florida | Procédé et composition de soulagement de la douleur |
AU2004319105A1 (en) | 2004-03-29 | 2005-11-10 | Mediquest Therapeutics, Inc. | Polyamine analogs that activate antizyme frameshifting |
US7445794B1 (en) | 2004-04-29 | 2008-11-04 | The Regents Of The University Of Colorado | Methods for treating human proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors |
US8912214B2 (en) | 2005-07-29 | 2014-12-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of Chk2 kinase inhibitors for cancer treatment |
WO2007040535A1 (fr) | 2005-10-03 | 2007-04-12 | Cellgate, Inc. | Utilisation d'analogues de polyamine pour le traitement et la prévention de polypes intestinaux |
US20080026209A1 (en) * | 2006-07-28 | 2008-01-31 | Sunitha Grandhee | Automotive panel having polyurethane primer |
US20110091418A1 (en) | 2006-09-25 | 2011-04-21 | Pathlogica, LLC | Methods for treating viral infections using polyamine analogs |
WO2008112251A1 (fr) | 2007-03-14 | 2008-09-18 | Progen Pharmaceuticals, Inc. | Analogues de polyamine contenant des groupes cyclopropyle comme thérapies de la maladie |
WO2009018368A1 (fr) * | 2007-07-30 | 2009-02-05 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Traitement d'association à base d'amplificateur du nmda (n-méthyl-d-aspartate), d'inhibiteur de transporteur de glycine, d'inhibiteur de d-amino acide oxydase pour des troubles neuropsychiatriques |
ES2715173T3 (es) | 2009-07-16 | 2019-06-03 | Pathologica Llc | Producto farmacéutico para administración oral que comprende MGBG y métodos de tratamiento de enfermedades |
US9675566B2 (en) | 2009-07-16 | 2017-06-13 | Pathologica Llc | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing |
EP2283830A1 (fr) | 2009-07-23 | 2011-02-16 | Actogenix N.V. | Revêtement de capsule entérique aqueuse |
EP2665471B1 (fr) | 2011-01-19 | 2017-12-27 | Pathologica, LLC. | Formes posologiques pharmaceutiques orales à libération contrôlée comprenant de la mgbg |
EP2943189B1 (fr) | 2013-01-08 | 2021-03-10 | Pathologica LLC | Mitoguazone pour le traitement de la sclérose en plaques progressive |
-
2010
- 2010-07-16 ES ES10800602T patent/ES2715173T3/es active Active
- 2010-07-16 AU AU2010273277A patent/AU2010273277B2/en not_active Ceased
- 2010-07-16 BR BR112012000862A patent/BR112012000862A8/pt not_active Application Discontinuation
- 2010-07-16 NZ NZ715686A patent/NZ715686A/en not_active IP Right Cessation
- 2010-07-16 CA CA2768018A patent/CA2768018C/fr active Active
- 2010-07-16 US US12/837,753 patent/US8258186B2/en active Active
- 2010-07-16 JP JP2012520810A patent/JP6112449B2/ja active Active
- 2010-07-16 NZ NZ628513A patent/NZ628513A/en not_active IP Right Cessation
- 2010-07-16 DK DK10800602.4T patent/DK2453886T3/en active
- 2010-07-16 NZ NZ597488A patent/NZ597488A/en not_active IP Right Cessation
- 2010-07-16 EP EP10800602.4A patent/EP2453886B1/fr active Active
- 2010-07-16 WO PCT/US2010/042253 patent/WO2011009039A2/fr active Application Filing
- 2010-07-16 EP EP18210165.9A patent/EP3473247A1/fr not_active Ceased
- 2010-07-16 CN CN201080041853.XA patent/CN102686222B/zh active Active
- 2010-07-16 CN CN201510274080.4A patent/CN104997762B/zh active Active
-
2012
- 2012-07-24 US US13/556,948 patent/US8609734B2/en active Active
-
2013
- 2013-03-18 HK HK13103363.8A patent/HK1176548A1/xx not_active IP Right Cessation
- 2013-10-25 US US14/063,541 patent/US9616035B2/en active Active
-
2015
- 2015-09-11 JP JP2015180110A patent/JP2016065045A/ja active Pending
-
2016
- 2016-12-01 AU AU2016266049A patent/AU2016266049B2/en not_active Ceased
-
2017
- 2017-02-23 US US15/441,122 patent/US20170290788A1/en not_active Abandoned
-
2018
- 2018-03-06 JP JP2018040226A patent/JP6883930B2/ja active Active
-
2019
- 2019-11-26 JP JP2019213582A patent/JP2020063258A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5614557A (en) * | 1977-07-11 | 1997-03-25 | Marion Merrell Et Compagnie C/O Merrell Pharmaceuticals Inc. | Method of controlling tumor growth rate |
US20050159493A1 (en) * | 1997-10-27 | 2005-07-21 | Mcgrath Michael S. | Methods for modulating macrophage proliferation using polyamine analogs |
US20070078187A1 (en) * | 2005-09-23 | 2007-04-05 | Pathologica, Llc. | Methods for treating viral infections using polyamine analogs |
US20080262092A1 (en) * | 2007-03-09 | 2008-10-23 | Pathologica Llc. | Regulation of osteopontin |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011009039A3 (fr) | Produit pharmaceutique pour administration par voie orale comprenant mgbg et procédés de traitement de maladie | |
UA99284C2 (ru) | ИНГИБИТОРЫ р70 S6-КИНАЗЫ | |
TN2011000414A1 (en) | Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitors, and uses thereof | |
MX2012004780A (es) | Inhibidores de akt. | |
MX2011002966A (es) | Formas de dosificacion farmaceutica que comprenden poli (e-caprolactona). | |
IN2012DN02805A (fr) | ||
MX2009007944A (es) | Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium. | |
WO2012021629A3 (fr) | Nouveaux agonistes du récepteur dopaminergique d3 pour traiter la dyskinésie dans la maladie de parkinson | |
UA103930C2 (ru) | Соединения и композиция для лечения паразитарных болезней | |
WO2009152356A3 (fr) | Composés et compositions utiles pour le traitement de la malaria | |
MX343135B (es) | Compuestos de tipo fumagilol y métodos de realización y uso de los mismos. | |
EP2007398A4 (fr) | Vitesses d'administration élevées pour préparations médicamenteuses lipidiques et méthodes de traitement associées | |
IL208203A (en) | Annotations of 3,2-Dihydro-Pyrido-4,1-Exazine and 3,2-Dihydro-4-Oxa-9,1-Diazapananthrene, Preparation Processes and Pharmaceutical Preparations | |
WO2010003313A8 (fr) | Chlorhydrate d’icotinib, synthèse, forme cristallographique, combinaison médicale et utilisations | |
EP2431366A4 (fr) | Nouveau composé conjugué de chlore e6-acide folique, procédé de préparation de ce composé et composition pharmaceutique contenant ledit composé pour le traitement du cancer | |
WO2009085270A3 (fr) | Traitement d'états fibreux | |
MX360554B (es) | Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2. | |
WO2012070062A3 (fr) | Nouveau polymorphe de chlorhydrate de nilotinib | |
ZA201203281B (en) | Pharmaceutical combinations, pharmaceutical compositions, medicament and method for the treatment of animals | |
EA201001747A1 (ru) | Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств | |
WO2008129501A3 (fr) | Compositions pharmaceutiques de duloxetine | |
WO2012100043A3 (fr) | Formes posologiques pharmaceutiques orales à libération contrôlée comprenant de la mgbg | |
WO2009032843A3 (fr) | Aminoalcools substitués | |
WO2009142428A3 (fr) | Composition pharmaceutique destinée au traitement de l'éjaculation précoce | |
MX367327B (es) | Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080041853.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10800602 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010273277 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 80/MUMNP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010800602 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2768018 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012520810 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2010273277 Country of ref document: AU Date of ref document: 20100716 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012000862 Country of ref document: BR |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112012000862 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012000862 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120113 |